TAI SHAN: This study is evaluating how safe, tolerable and effective a new drug is in people with relapsed or refractory B-cell Non-Hodgkin LymphomaA Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Exclusion

1. Have unresolved adverse drug reactions (except for alopecia) of higher than grade 1 (as defined by CTCAE v5.0) before the start of dosing in the study.
2. A history of anticancer treatment within washout period as defined in the protocol.
3. Participants with B-NHL other than CNSL who have central nervous system or intraocular lymphoma lesions.

4. Participants with CNSL who have the following health conditions:

   1. Unable to cooperate with a lumbar puncture or cerebrospinal fluid test.
   2. Involvement of sites outside the CNS requiring systemic therapy.
   3. Participants with condition requiring systemic glucocorticoid therapy at a dose of > 8 mg/day (dexamethasone equivalent dose); or participants requiring immunosuppressant or biologic therapy.
5. Active infectious diseases, including HBC, HCV, HIV, TB, etc.
6. Abnormal heart and lung function.
7. Refractory nausea and vomiting not well controlled by supportive care, chronic gastrointestinal disease, dysphagia, or previous surgical resection of bowel segments that may interfere with adequate drug absorption.
8. Participants diagnosed with other malignancies apart from B-cell lymphoma within the past 5 years. However, participants may also be enrolled if the current evidence shows that the participant has been clinically cured and the investigator believes that the potential benefit of treatment with DZD8586 outweighs the potential risk.
9. Participants with hypersensitivity to DZD8586 pharmaceutical excipients or other chemical analogs.
10. Participants with serious or poorly controlled systemic diseases as judged by the investigator or other evidence, including poorly controlled hypertension and active bleeding disorders.
11. Personnel involved in the planning and implementation of this study (only applicable to employees of the sponsor and study site).
12. Female participants who are breastfeeding or pregnant.
13. Participants who have taken DZD8586.
14. Participants should not participate in the study if they are considered by the investigator to be unlikely to comply with study procedures, restrictions, and requirements.